IR@PKUHSC  > 北京大学第二临床医学院  > 骨肿瘤科
学科主题临床医学
Sorafenib Induces Growth Inhibition and Apoptosis of Human Chondrosarcoma Cells by Blocking the RAF/ERK/MEK Pathway
Lu, Xinchang; Tang, Xiaodong; Guo, Wei; Ren, Tingting; Zhao, Hui
关键词chondrosarcoma sorafenib MAPK apoptosis
刊名JOURNAL OF SURGICAL ONCOLOGY
2010-12-01
DOI10.1002/jso.21661
102期:7页:821-826
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology ; Surgery
研究领域[WOS]Oncology ; Surgery
关键词[WOS]DOWN-REGULATION ; CANCER ; P38 ; BAY-43-9006 ; CARCINOMA ; MIGRATION ; SARCOMA ; ERK
英文摘要

Background: Chondrosarcoma represents the second most common primary malignant bone tumor causing significant morbidity due to local recurrence and limited treatment options. Conventional cytotoxic chemotherapy has been proven to be largely ineffective to this sarcoma. Here we report that sorafenib is effective in growth inhibition of chondrosarcoma cell lines in vitro.

Methods: Chondrosarcoma cell lines (SW 1353 and CRL7891) were treated with sorafenib. Flow cytometry, DAPI assay, and Western blotting were employed to determine the effects of sorafenib in inhibitory proliferation and induce apoptosis in chondrosarcoma cells in vitro.

Results: The results showed that sorafenib effectively inhibited cell growth and induced apoptosis in chondrosarcoma cells, which was concurrent with inhibition of the expression of phospho-MEK and phospho-ERK. Further more the expression levels of cyclin D1, Rb and anti-apoptotic proteins Bcl-xl and Mcl-1 significantly reduced, but no changes in Bcl-2 and Bax. We although detected the expression of Akt, JNK, p38 and their respective phosphoprotein, but did not found meaningful changes.

Conclusions: Our findings demonstrate that sorafenib inhibited the Ras/Raf/MAPK pathway in a time-and dose-dependent fashion in chondrosarcoma cell lines SW 1353 and CRL7891 and suggest that sorafenib may be a new therapeutic option for patients with chondrosarcorna. J. Surg. Oncol. 2010;102:821-826. (C) 2010 Wiley-Liss, Inc.

语种英语
WOS记录号WOS:000285281300022
引用统计
被引频次:14[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/66468
专题北京大学第二临床医学院_骨肿瘤科
北京大学药学院_天然药物与仿生药物国家重点实验室
作者单位Peking Univ, Musculoskeletal Tumor Ctr, Peoples Hosp, Beijing 100044, Peoples R China
推荐引用方式
GB/T 7714
Lu, Xinchang,Tang, Xiaodong,Guo, Wei,et al. Sorafenib Induces Growth Inhibition and Apoptosis of Human Chondrosarcoma Cells by Blocking the RAF/ERK/MEK Pathway[J]. JOURNAL OF SURGICAL ONCOLOGY,2010,102(7):821-826.
APA Lu, Xinchang,Tang, Xiaodong,Guo, Wei,Ren, Tingting,&Zhao, Hui.(2010).Sorafenib Induces Growth Inhibition and Apoptosis of Human Chondrosarcoma Cells by Blocking the RAF/ERK/MEK Pathway.JOURNAL OF SURGICAL ONCOLOGY,102(7),821-826.
MLA Lu, Xinchang,et al."Sorafenib Induces Growth Inhibition and Apoptosis of Human Chondrosarcoma Cells by Blocking the RAF/ERK/MEK Pathway".JOURNAL OF SURGICAL ONCOLOGY 102.7(2010):821-826.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Lu, Xinchang]的文章
[Tang, Xiaodong]的文章
[Guo, Wei]的文章
百度学术
百度学术中相似的文章
[Lu, Xinchang]的文章
[Tang, Xiaodong]的文章
[Guo, Wei]的文章
必应学术
必应学术中相似的文章
[Lu, Xinchang]的文章
[Tang, Xiaodong]的文章
[Guo, Wei]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。